Peptide Pete 🧬

peptide and longevity research made easy. I’m a cartoon not a doctor👇 Full breakdowns

[Peptide Pete 🧬 @thepeptidebuzz]

Not all peptides are equal. So I ranked them.

Every peptide I cover on Straight Up Peptides, sorted by how much human evidence actually backs it, strongest to weakest.

Each one gets a straight answer on:

- how strong the human evidence is
- its FDA status
- how it works in the body
- what human studies found, and what's still only rats and petri dishes

Semaglutide sits near the top. FDA-approved, huge human trials.

BPC-157, the one everyone's injecting for recovery, sits near the bottom. Almost all of its research is animal or lab work.

Know the science before you buy the hype:
https://t.co/TCvcZ81Oj3

[Reptides @reptidesco]

Hims & Hers ($HIMS) says Peptides+ is expected to launch by the end of November, with BPC-157 and TB-500 planned to follow when regulations permit.

The company outlined the offering during its Nov 9 earnings call:

> Initial treatments include sermorelin, glutathione, NAD+ and B12
> Personalized treatment plans overseen by clinicians
> Access to regular blood testing and ongoing clinical support
> BPC-157 and TB-500 availability remains dependent on the regulatory environment

Hims also says it plans to manufacture the raw active ingredients for BPC-157 and TB-500 at its Menlo Park, California facility.

[Peptide Pete 🧬 @thepeptidebuzz]

@PeterDiamandis the 50 year old waiting for a doctor's note to start lifting needs to read this twice. the barbell doesn't check id 💪

[Peptide Pete 🧬 @thepeptidebuzz]

@KrittanawongMD treating the fat is treating the heart, and select backed it. semaglutide cut heart attacks, strokes and cardiac deaths 20% in people with heart disease and no diabetes

[Peptide Pete 🧬 @thepeptidebuzz]

What both labels say about hair loss, plus the vitamins people try for it and what's in each:
https://t.co/Dvxuz2evei

[Peptide Pete 🧬 @thepeptidebuzz]

3% of people on Wegovy reported hair loss in the weight-loss trials. On placebo it was 1%.

Zepbound's number was bigger for women: 7.1% vs 1.3% on placebo.

Both labels tie the hair loss to the weight coming off. I looked for a vitamin trial that reverses it and couldn't find one.

Did you notice shedding, and how many months in did it start?

[Peptide Pete 🧬 @thepeptidebuzz]

@hormonedietdoc the good ones say "here's what the trials show and here's what we still don't know." the papal decree types skip the second half

[Peptide Pete 🧬 @thepeptidebuzz]

@bryan_johnson a mean of 79 is wild. most of us see that number once a year at the fasting blood draw and never again 😂

[Peptide Pete 🧬 @thepeptidebuzz]

@afshineemrani fib-4 should print on every lab report by default. fatty liver shows up in about 30% of adults worldwide and the math is free

[Submission Strong @submission_suds]

People who kept training their free arm while the other one sat in a cast for 4 weeks lost almost no strength in the casted arm. The group that didn't train lost about 22%.

Researchers call it cross-education. You train one side, and the opposite side holds on to strength it would otherwise lose. They think most of it runs through your nervous system.

We're not doctors, but we read research all day, and this one is for anyone still rolling in their 40s who keeps getting hurt one side at a time. These are the 3 trials I found with hard numbers:

1. Andrushko 2018. 16 college students wore a cast on one forearm for 4 weeks. Half of them did slow-lowering wrist curls with the free arm 3 times a week. Casted-arm wrist strength dropped 2.4% in the training group and 21.6% in the group that didn't train. Muscle size held up too.

2. Magnus 2013. 51 women over 50 with a broken wrist. Everyone got normal rehab, and half also strength-trained the good hand at home 3 times a week. At 12 weeks the broken side gripped 17.3 kg vs 11.8 kg. By 26 weeks the gap was no longer significant.

3. Harput 2019. 48 people after ACL surgery. Starting 4 weeks after surgery, two groups trained the healthy leg 3 times a week for 8 weeks. Both got more quad strength back in the surgery leg than the rehab-only group, at 12 and 24 weeks.

How I'd use it after an injury:

Train the healthy side with the same movement, because the effect stayed with the muscle that was trained. In the cast study, wrist curls saved the wrist flexors and did nothing for the extensors.

Start early. Both injury trials started within the first month.

Three sessions a week was the schedule in all three trials.

These are small trials, and the cast study used healthy students with no actual injury. The wrist fracture edge faded by 26 weeks, and the ACL groups didn't hop any farther or score better on the knee questionnaire.

Clear any training around an injury with your doctor or physio first, especially after surgery.

My take: sitting on the couch while one limb heals throws away strength you could keep. When you got hurt last, did anyone tell you to keep training the other side?

[Peptide Pete 🧬 @thepeptidebuzz]

@AdrienEmber @NeilFlochMD pretty much. it works while you're on it, the same way a diet works while you stick to it. that's why you want a plan for coming off before you stop

[Peptide Pete 🧬 @thepeptidebuzz]

@alokgangaramany yep, refill data would at least pin down when people stopped. the why is tougher, since feeling sick or the price going up doesn't get a diagnosis code

[Peptide Pete 🧬 @thepeptidebuzz]

About double. That's how much higher the rate of heart attack, stroke or death was in Italians with type 2 diabetes who stopped their GLP-1, compared with people who stayed on it.

80,302 people, 301 diabetes clinics, 20 years of records. It came out this week in The Lancet Regional Health Europe, and the "stopping Ozempic" headlines followed.

I read the published summary and what three outside experts said about it. These are the 5 checks I ran, and you can run them on the next scary GLP-1 headline:

1. Check if it was a trial. This one was records. Nobody was told to stop, so it can show a link but it can't show cause.

2. Ask why people stopped. The study didn't record it. Side effects or a new illness can push someone off a drug and raise their heart risk at the same time.

3. Check which drug. Most people here were on liraglutide or dulaglutide. Nobody was on tirzepatide, and only a few were on semaglutide.

4. Check who was in it. Everyone had type 2 diabetes and no heart disease at the start. It doesn't cover people on Wegovy or Zepbound for weight alone.

5. Check the comparison group. It was people who stayed on. It can't tell you if stopping left anyone worse off than never starting.

Save this for the next one: trial or records, why they stopped, which drug, who was in it, compared to what.

My take: this doesn't prove stopping hurts your heart. It's still a good reason not to quit on your own, so if you want off, make the plan with your doctor.

If you came off one, did your doctor give you a plan?

[Peptide Pete 🧬 @thepeptidebuzz]

Where Wegovy's liver approval stands in the US and Canada, next to every other approved GLP-1:
https://t.co/xlFxfyAV2W

[Peptide Pete 🧬 @thepeptidebuzz]

53%. That's how many people on plain semaglutide, the drug in Wegovy, cleared their liver inflammation in Merck's new fatty liver trial. Merck's experimental drug got 56% to 63%.

The drug is efinopegdutide, a weekly shot that hits GLP-1 and glucagon receptors. The trial had 381 adults with MASH, the inflamed kind of fatty liver, plus moderate to advanced scarring. It ran 52 weeks and came out Nov 9 in The Lancet.

I read Merck's press release. It puts its drug next to placebo's 13% and never gives semaglutide's liver result. Semaglutide only comes up in the trial design and the side effects. I found the 53% in the conference coverage.

Three more things from the results:

1. Nobody tested the two drugs against each other. The semaglutide group knew what they were on, and the researcher who presented the trial said it wasn't a direct comparison.

2. The real gap was scarring. At the middle dose, 52% saw their scarring improve by at least one stage. Semaglutide got 25% and placebo got 21%.

3. The top dose didn't beat placebo on scarring, and 11% of people on it quit over side effects.

Wegovy already has accelerated FDA approval for this liver disease. Efinopegdutide is still experimental, and this was a phase 2 trial. The results are liver biopsies at one year, so they can't tell you yet whether fewer people end up with cirrhosis.

My take: the scarring result is worth watching, because scarring is what turns into cirrhosis. But the press release left out how close semaglutide came, and that's the number people already on it would want.

Has your doctor ever checked your liver while you've been on a GLP-1?

[Peptide Pete 🧬 @thepeptidebuzz]

@DrKristieLeong bird dog looks like the easiest move in the gym until you do it slow and your hips start rocking. humbling at any age

[Peptide Pete 🧬 @thepeptidebuzz]

@DrNadolsky lifting on tirzepatide should be the default, not the bonus. in the surmount-1 scans lean mass still dropped about 11% next to 34% for fat, so there's room to save more

[Peptide Pete 🧬 @thepeptidebuzz]

@BenBikmanPhD ground beef supremacy. cheaper, more protein per bite, and you don't have to pretend you know what medium rare looks like 😂

[Submission Strong @submission_suds]

Monohydrate is the form almost all the creatine research was done on, and it costs less. HCl mixes better and some guys say it's easier on the stomach. If plain mono doesn't bother you, there's no reason to pay more.

[Peptide Pete 🧬 @thepeptidebuzz]

@researchitgg yep, and it's an interim policy with the comment window still open, so it can change. a spot on the bulks list is the thing that would last

[Peptide Pete 🧬 @thepeptidebuzz]

6 peptides. HHS said it will not take enforcement action against 503A compounding of BPC-157, TB-500, MOTS-c, KPV, Epitalon and Semax. That is discretion, not FDA approval, and none of the six are on the 503A Bulks List. What changed, and what didn't, is in the first reply.

[Peptide Pete 🧬 @thepeptidebuzz]

@KrittanawongMD yep. 40% vs 19% on doctor certainty is a nice number, but your arteries don't care how sure anyone felt. waiting on the follow-up that counts heart attacks